Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Xbrane Biopharma, Webcast, Q2'26

By Inderes7/17/2026, 7:00 AM
Xbrane Biopharma

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Martin
00:00 - 10:26

Hello, everybody, and welcome to our webcast in relation to the Q2 report 2026 of Extreme Biopharma. As usual, I will go through an operational update of the quarter, and then Jane will go through a financial update. We'll start off with our biosimilar to Lucentis, which is on the market in Europe and commercialized by our commercialization partner Stardom. Those of you who have followed us know the arrangement; we share the profit contribution 50/50 of the sales, and it is currently launched across 24 countries in Europe and a few countries in the Middle East. It is a sizeable market opportunity. We are addressing a €5 billion steadily growing market, although facing somewhat increasing competition in relation to biosimilars to EYLEA gradually coming to the market in Europe as well as in the US. Looking at the current quarter, we are still at a market share of around 7% from a volume perspective. We are releasing this Q2 report quite early, so we haven't received the final data for the quarter in relation to units sold. But, 7% volume market share as of April 2026. What you can see from the financial figures in the report is that we have resumed the shipments of final goods to Stardom during the quarter, and that is expected to remain the case during the remaining quarters of the year. Accumulated. We have now achieved a profit sharing of 127 million Swedish kronor. We are also, as we've been discussing before, working intensively to reduce our production costs across a multitude of different measures we're going through. And we expect that this will have a significant impact on the production costs, which will be realized from 2027 and onwards. And as you can see also from the financials, although we had some one-off effects on the quarter on the production cost side, there is an improvement potential in the gross margin. And we expect that these production cost measures will impact gross margin positively. We also have an inventory, as we have had for some time. It is at the level of 175 million Swedish crowns of drug substance as well as drug product and finished goods. So still a quite sizable inventory on our balance sheet, which gradually now is being converted into cash as deliveries to Stardom have resumed. In relation to the regulatory process with the FDA in the US, as those of you who follow us might recall, we received a complete response letter in October last year. It was related to observations at one of the manufacturing sites involved in the production of the brand name in the US, which is intended to be Eylea, but it is still the same product. The Lucentis biosimilar candidate production site, which is a contract manufacturer for Extreme Biopharma, has now worked through all these observations and the related actions to remediate these observations. All documentation has been sent to the FDA, which resulted in us resubmitting the BLA to the FDA in April this year. And we now have a decision date in October this year. So, we hope, of course, that this time we can get an approval for the product in the US, and we are now making the appropriate preparations for the launch of the product in the US, provided an approval, of course. So we are making preparations together with our partner, Valorum. We are just going to commercialize the product in the US. Then moving over to our biosimilar candidate to Opdivo. We are quite excited about this program. It is going through a very intense development phase right now. Both on the whole CMC side, which is related to process validation on both the drug substance and drug product side and also the ongoing clinical trial. So we are targeting a submission of a BLA to the US FDA during the course of next year. Everything is moving according to plan to be able to achieve that. So we are quite excited about this program. We believe it to be of substantial potential given the size of the market and the originator product. And also, the level of competition in relation to the size of the opportunity. And then I wanted to spend a few minutes also on Xspray's biosimilar candidate to Darzalex. And here we entered into a co-development agreement with the CDMO Joint Biologics. A few weeks ago. So this is I think a quite interesting development and possibility for us to be able to take a step forward in the development of SAIGEN without having to invest into the product right now. I guess there is some background information regarding our biosimilar candidate Darzalex, which is a product being used in the treatment of multiple myeloma, a form of cancer. It is a sizable product with sales of 14 billion USD in 2025. The patent expires in 2029 in the US and two years later in Europe. And as far as we can tell, there are. In total, there are four development programs for biosimilar candidates to Darzalex. So I would probably say, given the size of this opportunity, also a quite low level of competition. And here, it is also worth noting that the product was initially launched as an intravenously administered product, but a lot of the volume has now moved over to subcutaneous. Subcutaneous administration formulation. And our development here is targeting both these formulations. And a few words about Joinn Biologics. Then it is a global CDMO based in the US and China, having a sizable production facility in China with significant capacity on the drug substance side. And we believe with the ability to produce at competitive cost levels, which is crucial, of course, for biosimilar development. Some words about the structure of this arrangement. So essentially, Joint will continue, based on where we are at in this development. Joint will develop the production process and demonstrate the analytical similarity, performing all analytical development work to demonstrate analytical similarity versus the originator. And that is the first step really. And that is under Joint's responsibility and provided a successful outcome on that step in the development. The parties, Xbrane and Joint, will co-own the program and then Xbrane will lead the effort to find a suitable commercialization partner for this program. And then, take the further steps into clinical and regulatory development. Our ambition is, of course, to get the majority of those steps financed by a commercialization partner. While the steps related to scale-up, process characterization, validation, and eventually commercial manufacturing will be performed by Joint Biologics. We are quite excited about this agreement and this collaboration, and actually the possibility for us to continue this program without having to invest significantly into the program at this point in time. So that was a brief operational update. And I am handing over to Jane for a financial update.

Jane
10:27 - 13:13

Yes. And so, as you might have read in the report, the revenue for the quarter amounted to 46.8 million Swedish kronor, whereof 46.6 million Swedish kronor relate to resumed shipments of finished goods to Stada. The cost of goods sold amounted to 44.4 million Swedish crowns, which gave us a gross margin of 5%. The low gross margin is a result of a revised accrued profit sharing from Stada amounting to 5.5 million Swedish crowns, and an inventory adjustment that amounted to 5.7 million Swedish crowns. Had these adjustments not been made, the gross margin would have amounted to 26%, which is more in line with our current expectations. However, we are also, as Martin said, working on decreasing production cost measures and investing in those together with our partners, and we are expecting that the sales will continue during the third quarter and also during the fourth quarter. The fixed cost amounted to 17 million Swedish crowns, whereof 7 million is related to administration costs and 10.1 million is related to R&D, out of which 2.7 million Swedish crowns are related to amortization of intangible assets. 12.5 million Swedish crowns have been capitalized as intangible assets. And as for the breakdown of the cash flow for the quarter, you can see that we have received 13 million from profit sharing, and we have put in 34 million Swedish kronor into the production of Opio, for which we have received revenue during the second quarter, but also revenue to come during the third and fourth quarters. And we have the fixed cost of 17 million Swedish crowns, received money from the sales of the first and second quarter amounting to 21 million Swedish crowns, and invested in X-division, amounting to 4 million Swedish crowns. All in all, the closing balance for the quarter was 49.5 million Swedish crowns, so the cash and cash equivalents amounted to almost 15 million Swedish crowns, and the operating cash flow amounted to -4.8 million Swedish crowns.

Martin
13:17 - 14:33

Yeah. So, the key takeaways are a constant market share from a volume perspective in Europe. And we are working through, which is a key focus when it comes to Europe now, to reduce the production cost. We believe that these measures will have an effect in 2027 and onwards and lead to a significant reduction in production cost and improvement in gross margin. And the decision date when it comes to the FDA approval is in October of this year. October of this year. So we hope, of course, for an FDA approval this time around and a subsequent launch of the product in the US, everything proceeding according to plan with Xdiv, targeting the BLA submission during the course of next year. And the co-development agreement signed with Joint Biologics and the ability for us to continue the development of X-star. So that's really the key takeaways from this quarter. So with that said, we leave over to any potential questions from listeners having called in.

Operator
14:36 - 14:54

If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Philip Einerson from Redeye. Please go ahead.

Philip Einerson
14:57 - 15:22

Okay. Hello, Martin and Jane. Thank you for taking a few questions from me. I have two to start with, if that is all right. So, firstly, in the report, you state an expectation of around a 50% reduction in production costs by 2027, which sounds like a significant achievement. Maybe you could elaborate a little bit on what you are doing to accomplish this.

Martin
15:25 - 16:02

It relates to a multitude of different process improvements we are really going through. It is not so much more we can say there, but yes, we do expect it to lead to significant cost reduction. And this is really the key when it comes to biosimilars, generally speaking, as the market has developed, to ensure that you have a reliable and cost-efficient supply chain. So that is really what we are working through and ensuring now when it comes to. Lucy.

Philip Einerson
16:04 - 16:14

Yeah. And would you say, is this an early 2027 or late 2027 target for this to be done?

Martin
16:15 - 16:22

So, I think the effects will gradually be seen from mid-2027 onwards.

Philip Einerson
16:25 - 16:52

Right. And then I also have another question. This goes back a while, but if I remember correctly, there was a disagreement between you and Valorum relating to the upfront payment. You updated the market on this. I think it was the end of 2024 or early 2025. Has there been any update on this topic since?

Martin
16:55 - 17:19

I think that there should not be an expectation of an upfront payment in relation to the US. It is still an ongoing discussion on the exact financials, but I think that is the right expectation to have.

Philip Einerson
17:21 - 17:27

Okay. So next stop then would be the date and what happens there.

Martin
17:28 - 17:38

Yes, exactly. And then, of course, income generation as a result of profit sharing from actual sales.

Philip Einerson
17:40 - 17:52

Right? And so maybe the last one for me then, how good of a proxy would you say the Q2 cash flow is for the remainder of 2026 quarters?

Martin
17:54 - 19:18

Yeah. We have, as we've said before and as written in the report, an expectation that we can sustain the business with our current cash position in the foreseeable future, where we are not counting on potential income from biosimilars in the US, but we are also not including the repayment of outstanding debt as we foresee or expect that the repayment of that debt could be done via proceeds coming from the US. But if you take those elements apart, given that the sales of Simlandi are proceeding according to existing forecasts, and our production of the product is proceeding according to existing plan, then we shall be able to sustain the business with our existing cash position for the foreseeable future. Meaning, of course, that we are fluctuating or we are at least starting to generate at some point in time positive cash flow, right? So it will go a little bit up and down. But I think we're starting to come to a level where you can use the cash flows being generated as a proxy for the future. Yeah.

Philip Einerson
19:20 - 19:24

Okay. Good. That was all for me. Thanks.

Operator
19:31 - 19:37

As a reminder, if you wish to ask a question, please dial pound key five on your telephone keypad.

Jane
19:41 - 19:43

Then we have a written question.

Martin
19:44 - 20:46

Yes. Can you please explain the license fee and whether it will increase in the future? So these income streams are discrete in relation to specific agreements which we are making. And what can be seen historically is mainly license fees being paid for Ex-Dwayne from our partner in the U.S. Now, as we mentioned, we are going to start an effort to out-license our Darzalex biosimilar candidate. Should we be successful in doing that? It could result in further license fees. But apart from that, we have very limited license fees to come in from existing agreements. So it is reliant upon us actually making new agreements. License fees are included for such an income stream to come back, if you will. Yeah.

Jane
20:50 - 20:54

Are there any changes regarding the agreement with Valorem?

Martin
20:54 - 21:13

I think we touched upon this, it is an ongoing discussion, but I think we explained what should be the reasonable expectations in relation to at least the potential upfront. And so, what is the point? We will have to get back to you as soon as any formal changes are made to that agreement. Yeah.

Operator
21:15 - 21:21

There are no more questions at this time. So I hand the conference back to the speakers for any closing comments.

Martin
21:24 - 21:33

So thank you all for calling in, and I wish you all a good day. And should you have any further questions, please do reach out to us. Thank you.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…